Skip to content Norwegian Medical Products Agency Norwegian Medical Products Agency

FHIR Service

Published:

Changes

The FHIR Service, part of the SAFEST project, aims to provide structured medicinal product information for hospitals. It is developed in collaboration with the Regional Health Authorities (RHFs) and the Norwegian Medical Products Agency (NOMA).

The FHIR Service is a master data service for medicinal products developed by NOMA to meet the specialist healthcare sector’s need for more structured medicinal product information than what is provided by the FEST service. The FEST service was originally developed for the e-prescription chain. Its current use within specialist healthcare requires resource-intensive adaptations. NOMA has therefore developed a source of structured medicinal product information based on the global ISO IDMP standard.

Once fully developed, the service will cover five key areas of need:

  • Unique, structured, and standardized master data (e.g., authorized medicinal products, manufactured products, administrable medicinal products, active substances and strengths, packaging information, nutritional information, etc.).
  • Grouping of medicinal products (PhPID)  to support active substance-based prescribing in hospitals and the prescription of medicines to be shared nationally between different healthcare actors and internationally between different countries.
  • Detailed information on different packaging levels, including associated product codes (barcodes), down to singel-dose packages, to support closed-loop medication management in healthcare institutions.
  • Structured information on the nutritional content of nutritional products to support nutritional accounting.
  • Linking substances to ATC codes.

The solution is designed to be future-oriented, based on international standards (ISO IDMP), and scalable. NOMA also collaborates with the RHF's H-prescription project to ensure that the FHIR Service provides data to support the prescribing and dispensing of H-prescriptions. In addition, the FHIR Service will be expanded to include pricing data for medicinal products prescribed under the Blue Prescription reimbursement scheme.